Intrathecal methotrexate is a standard option for central nervous system-directed therapy in patients with stage III and IV diffuse large B-cell lymphoma. We present a case of a 50-year-old man with stage IV diffuse large B-cell lymphoma with widespread lymphomatous involvement including the central nervous system, who received 7 doses of intrathecal methotrexate via Ommaya catheter. Posttherapy 18 F-FDG-PET/CT imaging demonstrated diffuse, intense intrathecal FDG avidity, without correlative findings on MR spinal imaging. FDG avidity resolved on follow-up. These PET/CT findings are most consistent with methotrexate-induced thecal inflammation, which needs to be distinguished from intrathecal malignancy.
. A 50-year-old man with stage IV high-grade diffuse large B-cell lymphoma (DLBCL) developed right orbital pain and proptosis in August 2013. MRI of the brain revealed a right orbital mass extending into the cavernous sinus, and cerebrospinal fluid analysis was positive for lymphoma cells, confirming central nervous system (CNS) involvement with lymphoma. An Ommaya catheter was placed, and the patient received 7 weekly doses of intrathecal methotrexate via the Ommaya catheter. Intrathecal methotrexate, in addition to systemic therapy, is a standard treatment regimen for III/IV DLBCL with concurrent CNS involvement, as described by the National Comprehensive Cancer Network. 1 Staging PET/CT was performed in November 2013. (A), FDG PET MIP, (B) sagittal FDG PET, and (C) sagittal CT scan demonstrate diffuse, intense FDG uptake throughout the thecal sac with extension into the neural foramina bilaterally, from the lower cervical through the sacral spine. Of note, anatomically, the thecal sac extends into the neural foramina. 2 As noncontrast CT did not provide adequate anatomic correlation for the intrathecal FDG avidity, spinal MR was performed.
Spinal MR was performed for correlation with FDG PET/CT findings. A, Sagittal T2 MR was normal, without abnormal signal within the cord or mass in the thecal space. B, Postcontrast sagittal T1 MR was also normal, without abnormal enhancement in the cord or thecal sac. Given the lack of an anatomic correlate for the extensive FDG avidity in the thecal sac, the FDG avidity was diagnosed as inflammatory, secondary to intrathecal methotrexate therapy, rather than lymphomatous involvement. providing further evidence that the initial intrathecal FDG avidity was benign. While CNS relapse in patients with DLBCL is rare, particularly in the postrituximab era, it carries an extremely poor prognosis. 3 Central nervous system-directed therapy with intrathecal methotrexate has been shown to decrease recurrence rates, particularly in aggressive subtypes of diffuse lymphoma. [4] [5] [6] Intrathecal methotrexate, however, is not without adverse effects. Specifically, cases of myelopathy, leukoencephalopathy, and cauda equina syndrome have been reported. [7] [8] [9] [10] Our case demonstrates a unique potential pitfall of FDG PET/CT, intrathecal inflammation from directed intrathecal chemotherapy. Leptomeningeal lymphoma would have been expected to demonstrate pronounced findings on MRI, including dural and nerve root enhancement. 11 In our case, no MR abnormality corresponded to the intense intrathecal FDG avidity seen on FDG PET/CT, supporting the diagnosis of an inflammatory response related to intrathecal therapy. Our case emphasizes the importance of adequate anatomic correlation for FDG-avid intrathecal findings.
